Transitions Optical Archives - Page 20 of 21

Transitions and Vision RX Lab Team Up to Host CE Event for ECPS

Friday, November 4 2016 | 00 h 00 min | Events, News

With the potentially harmful effects of blue light, eye care professionals need to be aware of ALL the sources and the products available to protect...

Transitions Optical Continues Transitions Innovation Awards Program

Tuesday, September 27 2016 | 00 h 00 min | News, Press Release

LAS VEGAS – Industry professionals can begin submitting nominations for the 2016 Transitions Innovation Awards Program on October 1 Through the...

Transitions Optical 2016 Consumer Campaign Expands

Thursday, February 11 2016 | 00 h 00 min | News, Press Release

ORLANDO, Fla– Allowing digital’s ever-increasing influence to complement the reach of traditional advertising techniques, Transitions Optical,...

Transitions Optical Reveals Transitions Innovation Awards Finalists

Friday, December 18 2015 | 00 h 00 min | Press Release

PINELLAS PARK, Fla– Transitions Optical, Inc has named the finalists for its new Transitions Innovation Awards program, which recognizes both...

Transitions Research: Are You Underserving Multicultural Patients?

Friday, December 11 2015 | 00 h 00 min | News, Press Release

PINELLAS PARK, Fla - While the vast majority of Canadian eye care professionals (93%) say they serve culturally diverse patients, 40% admit that...

« Previous 1 … 18 19 20 21 Next »

Gene Therapy for Wet AMD: Phase 1/2 Clinical Trial Results

A new study published in The Lancet shared results from a Phase 1/2 clinical trial testing a one-time anti-VEGF gene therapy for wet age-related macular degeneration (wet AMD).

Learn More

CooperVision Hosts Canadian ECPs for Innovation Tour in Costa Rica

CooperVision recently hosted an Innovation Tour for 20 eye care professionals from across Canada at its state-of-the-art, LEED® certified manufacturing facility located in San José, Costa Rica.

The Centre for Eye and Vision Research (CEVR) and SCOPE Health Inc. logos

CEVR and SCOPE Health Sign a MoU to Develop and Commercialize Novel Product Technologies for the Treatment of Dry Eye and Ocular Surface Conditions

The Centre for Eye and Vision Research (CEVR) and SCOPE Health Inc. have announced the signing of a Memorandum of Understanding (MoU) to establish a collaborative partnership focused on developing innovative technologies for dry eye disease and other ocular surface conditions.

Three New Peer Reviewed Papers Expand Myopia Management Evidence for SightGlass Vision Diffusion Optics Technology™

Works in BMJ Open Ophthalmology, Ophthalmic and Physiological Optics, and Translational Vision Science & Technology Focus on Efficacy, Vision, and Contrast Theory

VISIBILIA and Kappa® (BasicNet) Announce Exclusive Licensing Agreement

Visibilia and Kappa® have announced an exclusive licensing agreement for the design, production, and distribution of Kappa® eyewear.

Gene Therapy for Wet AMD: Phase 1/2 Clinical Trial Results

A new study published in The Lancet shared results from a Phase 1/2 clinical trial testing a one-time anti-VEGF gene therapy for wet age-related macular degeneration (wet AMD).

Learn More

CooperVision Hosts Canadian ECPs for Innovation Tour in Costa Rica

CooperVision recently hosted an Innovation Tour for 20 eye care professionals from across Canada at its state-of-the-art, LEED® certified manufacturing facility located in San José, Costa Rica.

CEVR and SCOPE Health Sign a MoU to Develop and Commercialize Novel Product Technologies for the Treatment of Dry Eye and Ocular Surface Conditions

Three New Peer Reviewed Papers Expand Myopia Management Evidence for SightGlass Vision Diffusion Optics Technology™

Works in BMJ Open Ophthalmology, Ophthalmic and Physiological Optics, and Translational Vision Science & Technology Focus on Efficacy, Vision, and Contrast Theory

VISIBILIA and Kappa® (BasicNet) Announce Exclusive Licensing Agreement

Visibilia and Kappa® have announced an exclusive licensing agreement for the design, production, and distribution of Kappa® eyewear.

Gene Therapy for Wet AMD: Phase 1/2 Clinical Trial Results

A new study published in The Lancet shared results from a Phase 1/2 clinical trial testing a one-time anti-VEGF gene therapy for wet age-related macular degeneration (wet AMD).

Learn More

CooperVision Hosts Canadian ECPs for Innovation Tour in Costa Rica

CooperVision recently hosted an Innovation Tour for 20 eye care professionals from across Canada at its state-of-the-art, LEED® certified manufacturing facility located in San José, Costa Rica.

CEVR and SCOPE Health Sign a MoU to Develop and Commercialize Novel Product Technologies for the Treatment of Dry Eye and Ocular Surface Conditions

Three New Peer Reviewed Papers Expand Myopia Management Evidence for SightGlass Vision Diffusion Optics Technology™

Works in BMJ Open Ophthalmology, Ophthalmic and Physiological Optics, and Translational Vision Science & Technology Focus on Efficacy, Vision, and Contrast Theory

VISIBILIA and Kappa® (BasicNet) Announce Exclusive Licensing Agreement

Visibilia and Kappa® have announced an exclusive licensing agreement for the design, production, and distribution of Kappa® eyewear.

Gene Therapy for Wet AMD: Phase 1/2 Clinical Trial Results

A new study published in The Lancet shared results from a Phase 1/2 clinical trial testing a one-time anti-VEGF gene therapy for wet age-related macular degeneration (wet AMD).

Learn More

CooperVision Hosts Canadian ECPs for Innovation Tour in Costa Rica

CooperVision recently hosted an Innovation Tour for 20 eye care professionals from across Canada at its state-of-the-art, LEED® certified manufacturing facility located in San José, Costa Rica.

CEVR and SCOPE Health Sign a MoU to Develop and Commercialize Novel Product Technologies for the Treatment of Dry Eye and Ocular Surface Conditions

Three New Peer Reviewed Papers Expand Myopia Management Evidence for SightGlass Vision Diffusion Optics Technology™

Works in BMJ Open Ophthalmology, Ophthalmic and Physiological Optics, and Translational Vision Science & Technology Focus on Efficacy, Vision, and Contrast Theory

VISIBILIA and Kappa® (BasicNet) Announce Exclusive Licensing Agreement

Visibilia and Kappa® have announced an exclusive licensing agreement for the design, production, and distribution of Kappa® eyewear.

Tag: Transitions Optical

Transitions and Vision RX Lab Team Up to Host CE Event for ECPS

Transitions Optical Continues Transitions Innovation Awards Program

Transitions Optical 2016 Consumer Campaign Expands

Transitions Optical Reveals Transitions Innovation Awards Finalists

Transitions Research: Are You Underserving Multicultural Patients?

Featured Posts

Gene Therapy for Wet AMD: Phase 1/2 Clinical Trial Results

CooperVision Hosts Canadian ECPs for Innovation Tour in Costa Rica

CEVR and SCOPE Health Sign a MoU to Develop and Commercialize Novel Product Technologies for the Treatment of Dry Eye and Ocular Surface Conditions

Three New Peer Reviewed Papers Expand Myopia Management Evidence for SightGlass Vision Diffusion Optics Technology™

VISIBILIA and Kappa® (BasicNet) Announce Exclusive Licensing Agreement

Gene Therapy for Wet AMD: Phase 1/2 Clinical Trial Results

CooperVision Hosts Canadian ECPs for Innovation Tour in Costa Rica

CEVR and SCOPE Health Sign a MoU to Develop and Commercialize Novel Product Technologies for the Treatment of Dry Eye and Ocular Surface Conditions

Three New Peer Reviewed Papers Expand Myopia Management Evidence for SightGlass Vision Diffusion Optics Technology™

VISIBILIA and Kappa® (BasicNet) Announce Exclusive Licensing Agreement

Gene Therapy for Wet AMD: Phase 1/2 Clinical Trial Results

CooperVision Hosts Canadian ECPs for Innovation Tour in Costa Rica

CEVR and SCOPE Health Sign a MoU to Develop and Commercialize Novel Product Technologies for the Treatment of Dry Eye and Ocular Surface Conditions

Three New Peer Reviewed Papers Expand Myopia Management Evidence for SightGlass Vision Diffusion Optics Technology™

VISIBILIA and Kappa® (BasicNet) Announce Exclusive Licensing Agreement

Gene Therapy for Wet AMD: Phase 1/2 Clinical Trial Results

CooperVision Hosts Canadian ECPs for Innovation Tour in Costa Rica

CEVR and SCOPE Health Sign a MoU to Develop and Commercialize Novel Product Technologies for the Treatment of Dry Eye and Ocular Surface Conditions

Three New Peer Reviewed Papers Expand Myopia Management Evidence for SightGlass Vision Diffusion Optics Technology™

VISIBILIA and Kappa® (BasicNet) Announce Exclusive Licensing Agreement